Glecirasib
生产企业：Jacobio Pharma (originator), Johnson & Johnson (partner)
JAB-21822 (glecirasib) is an oral small-molecule KRAS G12C inhibitor developed by Jacobio Pharma in partnership with Johnson & Johnson. It is currently in phase 3 clinical trials for non-small cell lung cancer (NSCLC) and colorectal cancer.
JAB-21822 (glecirasib) is an oral small-molecule KRAS G12C inhibitor developed by Jacobio Pharma in partnership with Johnson & Johnson. It is currently in phase 3 clinical trials for non-small cell lung cancer (NSCLC) and colorectal cancer.
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC) — phase 3 clinical trials
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
